Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 1:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 64 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pediatric Attention Deficit Hyperactivity Disorder Clear all
Completed Phase 1 Interventional

A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity Disorder

NCT04786730
View directory record Official record
Conditions
Attention-deficit Hyperactivity Disorder
Interventions
Centanafadine
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
4 Years to 12 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Little Rock, Arkansas • Decatur, Georgia • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Oct 20, 2026, 1:57 PM EDT
Completed Not applicable Interventional Results available

Software Treatment for Actively Reducing Severity of ADHD

NCT02674633
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
AKL-T01, AKL-T09
Device
Lead sponsor
Akili Interactive Labs, Inc.
Industry
Eligibility
8 Years to 12 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
20
States / cities
Dothan, Alabama • Scottsdale, Arizona • Newport Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2020 · Synced Oct 20, 2026, 1:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Behavioral Health Care for Children With ADHD

NCT02972086
View directory record Official record
Conditions
ADHD
Interventions
Behavioral Parent Training (BPT)
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 20, 2026, 1:57 PM EDT
Withdrawn Not applicable Interventional

Improving the Medication Management of Patients With Attention-Deficit Hyperactivity Disorder

NCT01769300
View directory record Official record
Conditions
Attention Deficit-hyperactivity Disorder
Interventions
Clinical decision support for medication titration
Behavioral
Lead sponsor
American Academy of Pediatrics
Other
Eligibility
5 Years to 12 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Elk Grove Village, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 13, 2018 · Synced Oct 20, 2026, 1:57 PM EDT
Completed Phase 3 Interventional

Efficacy, Safety, and Tolerability of Ambien (Zolpidem) in the Treatment of Children Ages 6 to 17 With Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia

NCT00318448
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Zolpidem (SL800750)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
6 Years to 17 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 7, 2009 · Synced Oct 20, 2026, 1:57 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Brain Imaging and Computer Games in Children With Either Bipolar Disorder, ADHD, Anxiety or Healthy Controls

NCT01570426
View directory record Official record
Conditions
Bipolar Disorder, Attention Deficit Disorder With Hyperactivity, Attention Deficit Disorder Without Hyperactivity, Generalized Anxiety Disorder, Healthy
Interventions
Not listed
Lead sponsor
Bradley Hospital
Other
Eligibility
7 Years to 17 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2018
U.S. locations
1
States / cities
East Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 20, 2026, 1:57 PM EDT
Recruiting Not applicable Interventional

Virtual Reality Attention Management

NCT03221244
View directory record Official record
Conditions
ADHD
Interventions
VR Treatment, VR Active Control
Device
Lead sponsor
University of California, Davis
Other
Eligibility
8 Years to 12 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 20, 2026, 1:57 PM EDT
Completed Not applicable Interventional Results available

Software Treatment for Actively Reducing Severity of ADHD - Follow Up

NCT02828644
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
EVO
Device
Lead sponsor
Akili Interactive Labs, Inc.
Industry
Eligibility
8 Years to 12 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
15
States / cities
Scottsdale, Arizona • Newport Beach, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 20, 2026, 1:57 PM EDT
Completed Phase 3 Interventional Results available

A Trial Evaluating the Efficacy and Safety of HLD200 in Children With ADHD

NCT02255513
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
HLD200, Placebo
Drug
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Other
Eligibility
6 Years to 12 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
4
States / cities
Newport Beach, California • Marshfield, Massachusetts • Las Vegas, Nevada + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 20, 2026, 1:57 PM EDT
Completed Phase 4 Interventional Results available

Characterization of Dermal Reactions in Pediatric Patients With ADHD Using DAYTRANA

NCT00434213
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Daytrana
Drug
Lead sponsor
Noven Therapeutics
Industry
Eligibility
6 Years to 12 Years
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
29
States / cities
Scottsdale, Arizona • Irvine, California • San Marcos, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 20, 2026, 1:57 PM EDT
Terminated Phase 3 Interventional Results available

Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)

NCT02691182
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
SPN-810
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 20, 2026, 1:57 PM EDT
Active, not recruiting Not applicable Interventional

Optimizing Attention and Sleep Intervention Study

NCT05683756
View directory record Official record
Conditions
Attention Deficit and Disruptive Behavior Disorders, Attention Deficit Hyperactivity Disorder, Child, Preschool, Sleep, Sleep Disturbance
Interventions
Brief Parent Behavioral Intervention, Sleep-Focused Parent Behavioral Intervention
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
3 Years to 5 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
Cranberry Township, Pennsylvania • Monroeville, Pennsylvania • New Castle, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 20, 2026, 1:57 PM EDT
Terminated No phase listed Observational

Retrospective of Children With ADHD and Cardiac Symptoms

NCT00266955
View directory record Official record
Conditions
Congenital Disorders
Interventions
Not listed
Lead sponsor
Children's Healthcare of Atlanta
Other
Eligibility
Up to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 6, 2011 · Synced Oct 20, 2026, 1:57 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Characterization and Brain Mechanisms of Frustration in Youth With Severe Irritability or Attention Deficit Hyperactivity Disorder (ADHD)

NCT05357495
View directory record Official record
Conditions
Disruptive Mood Dysregulation Disorder, Attention Deficit Hyperactivity Disorder, Normal Physiology
Interventions
Affective Posner fMRI frustration induction task
Behavioral
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
8 Years to 17 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Oct 20, 2026, 1:57 PM EDT
Terminated Phase 4 Interventional Results available

Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children

NCT04987762
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Adhansia XR
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
4 Years to 12 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Little Rock, Arkansas • Colorado Springs, Colorado • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Oct 20, 2026, 1:57 PM EDT
Completed Phase 4 Interventional Results available

Crossover Study to Evaluate the Efficacy of AR11 in Pediatric Patients With ADHD in a Laboratory Classroom Setting

NCT01986062
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
AR11, Placebo
Drug
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
7
States / cities
Bradenton, Florida • Maitland, Florida • South Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 20, 2026, 1:57 PM EDT
Completed Phase 2 Interventional Results available

Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Participants With Attention-deficit Hyperactivity Disorder (ADHD)

NCT04081363
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Centanafadine
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
9 Years to 12 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2023 · Synced Oct 20, 2026, 1:57 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder

NCT00922636
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
LY2216684, Methylphenidate, Placebo (tablet), Placebo (capsule)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 17 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
17
States / cities
Spring Valley, California • Bradenton, Florida • Gainesville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2014 · Synced Oct 20, 2026, 1:57 PM EDT
Completed Phase 3 Interventional

Efficacy, Tolerability and Safety of Dexmethylphenidate HCl Extended-Release Capsules in Children With Attention-Deficit/Hyperactivity Disorder

NCT00301236
View directory record Official record
Conditions
ADHD, ADD
Interventions
Dexmethylphenidate HCl extended-release capsules
Drug
Lead sponsor
Novartis
Industry
Eligibility
6 Years to 12 Years
Enrollment
252 participants
Timeline
2006
U.S. locations
25
States / cities
Mesa, Arizona • Little Rock, Arkansas • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2007 · Synced Oct 20, 2026, 1:57 PM EDT
Recruiting No phase listed Observational

Studies of Brain Function and Course of Illness in Pediatric Bipolar Disorder

NCT00025935
View directory record Official record
Conditions
Mood Disorder
Interventions
Lithium
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
7 Years to 85 Years
Enrollment
2,350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 20, 2026, 1:57 PM EDT
Recruiting Not applicable Interventional

SKIP for PA Study: Team and Leadership Level Implementation Support for Collaborative Care

NCT04946253
View directory record Official record
Conditions
Child Behavior Problem, Attention Deficit and Disruptive Behavior Disorders
Interventions
DOCC: Evidence-based treatment for disruptive behavior and ADHD, TEAM: Implementation support strategies at the care team level following standard implementation of DOCC, Implementation support strategies at the leadership level following standard implementation of DOCC
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 20, 2026, 1:57 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Multidimensional Measurement of Psychopharmacological Treatment Response

NCT01184235
View directory record Official record
Conditions
Autism Spectrum Disorders, Mood Disorders, Sleep Disorders, Attention Deficit Disorders
Interventions
Pharmacological Intervention
Drug
Lead sponsor
Child Psychopharmacology Institute
Other
Eligibility
6 Months and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 20, 2026, 1:57 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of an Intervention for Improving Community-based Pediatric Attention-Deficit Hyperactivity Disorder (ADHD) Care

NCT01143701
View directory record Official record
Conditions
ADHD
Interventions
ADHD Collaborative
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 11 Years
Enrollment
577 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 8, 2016 · Synced Oct 20, 2026, 1:57 PM EDT
Completed Phase 3 Interventional Results available

Quillivant Oral Suspension (Quillivant XR) in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)

NCT00904670
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Quillivant Oral Suspension XR, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 12 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
Irvine, California • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Oct 20, 2026, 1:57 PM EDT